Search results
Results from the WOW.Com Content Network
In the United Kingdom the BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018 [7] recommend: . On-demand or daily oral Tenofovir – emtricitabine (TD-FTC) for HIV-negative MSM who are at elevated risk of HIV acquisition through unprotected anal sex in the previous six months and ongoing unprotected anal sex.
Alive & Well AIDS Alternatives (formerly HEAL, Health Education AIDS Liaison) is a 501(c) non-profit organization of AIDS denialists. [1] The organization's stated mission is to "present information that raises questions about the accuracy of HIV tests, the safety and effectiveness of AIDS drug treatments, and the validity of most common assumptions about HIV and AIDS."
There are several treatment guidelines for HIV-1 infected adults in the developed world (that is, those countries with access to all or most therapies and laboratory tests). In the United States there are both the International AIDS Society-USA (IAS-USA) (a 501(c)(3) not-for-profit organization in the US) [ 47 ] as well as the US government's ...
The HIV Prevention Trials Network conducted a clinical trial, HPTN 052, that analyzed the effectiveness of antiretroviral drugs on the HIV-1 virus. 1,783 HIV sero-discordant couples, or couples that consist of an HIV-positive individual and an HIV-negative partner, from nine different countries were a part of the study, 97% of the couples being ...
Early treatment of HIV-infected people with antiretrovirals protected 96% of partners from infection. [ 43 ] [ 8 ] Pre-exposure prophylaxis with a daily dose of tenofovir with or without emtricitabine is effective in a number of groups, including men who have sex with men, couples where one is HIV positive, and young heterosexuals in Africa. [ 26 ]
It works by inhibiting the enzyme reverse transcriptase that HIV uses to make DNA and therefore decreases replication of the virus. [6] Zidovudine was first described in 1964. [7] It was resynthesized from a public-domain formula by Burroughs Wellcome. [8] It was approved in the United States in 1987 and was the first treatment for HIV.
The CDC recommends PEP for any HIV-negative person who has recently been exposed to HIV for any reason. [22] To be most effective, treatment should begin within an hour of exposure. [23] After 72 hours PEP is much less effective, and may not be effective at all. [22] Prophylactic treatment for HIV typically lasts four weeks. [22] [24]
The human immunodeficiency virus (HIV) [8] [9] [10] is a retrovirus [11] that attacks the immune system.It is a preventable disease. [5] There is no vaccine or cure for HIV. It can be managed with treatment and become a manageable chronic health condition. [5]